GANX
USDGain Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$1.810
Máximo
$1.810
Mínimo
$1.660
Volumen
0.57M
Fundamentos de la Empresa
Capitalización de Mercado
59.7M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.68M
Bolsa
NGM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
BTIG analyst Thomas Shrader reiterates Gain Therapeutics with a Buy and maintains $9 price target.
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics with a Buy and maintains $8 price target.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
Maxim Group analyst Jason McCarthy maintains Gain Therapeutics with a Buy and raises the price target from $5 to $7.
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to
Acciones Relacionadas
APM
Aptorum Group Limited Ordinary Shares
VGI
Virtus Global Multi-Sector Income Fund Common Shares of Beneficial Interest
GAINN
Gladstone Investment Corporation 5.00% Notes Due 2026
FAX
abrdn Asia-Pacific Income Fund Inc.
HTBI
HomeTrust Bancshares Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.